Medtronic Plc (MDT) presents itself as an attractive stock for investment given its steady dividend and profit growth. The Company recently announced a cash dividend for the fourth quarter of fiscal year 2025 and maintains a 47-year growth streak, cementing its status as one of the top-performing S&P 500 Dividend Stocks. This contributes to a solid long-term value, even with temporary dips in stock price. Medtronic has also reported strong growth in the cardiac sector and boasts impressive Q3 2025 earnings. It has notably welcomed a new CFO, Thierry Piéton, and continues to garner praise from host of CNBC's 'Mad Money', Jim Cramer. The firm's continual revenue growth and AI-driven advances signal high potential within medical therapies and spine surgery sectors. Additionally, Medtronic has its sights set on optimizing manufacturing operations amid tariff threats. The strong financial performance sees stock trades cheaper than peers, and persists in being a 'buy' option, even at $85. Medtronic also received U.S FDA approval for an adaptive deep brain stimulation system for Parkinson's patients. The stock remains desirable despite a recent minor slump due to an inventory hiccup.
Medtronic Plc MDT News Analytics from Thu, 09 May 2024 07:00:00 GMT to Mon, 10 Mar 2025 12:38:00 GMT -
Rating 5
- Innovation 2
- Information 7
- Rumor -2
